Abstract 851P
Background
Acute myeloid leukemia (AML) is a clonal malignancy of the stem cell precursors of the myeloid lineage associate with uncontrolled proliferation and impaired differentiation of hematopoietic stem cells. Among the different genes found amplified in AML, the oncogene MYC is one of the prognostic factors with an impact of AML. Albeit MYC is a well know factor associated with the uncontrolled proliferation of AML, the mechanism that led to the oncogenesis established by MYC are not well known. Zebrafish has recently emerged as a valid model organism to study cancer development because of its genetic accessibility.
Methods
After the generation of a transgenic zebrafish line expressing the human MYC under the control of the neutrophils-specific promoter lysozyme (lyz:hMYC), we proceeded with FACS analysis of adult whole kidney marrow (WKM) of lyz:hMYC fish. Immunohistochemical analysis (IHC) of whole zebrafish was made to check the infiltration of cells and possible metastasis. May-Grunwald stain was made to check the kidney marrow population. Gene expression profile of WKM was performed to check the expression of genes associated with myc and its patthway. We conducted a Metagenomic analysis on possible variations in the intestinal microbiota associated with the disease causing its progression.
Results
FACS analysis of lyz:hMYC zebrafish revealed the expansion of myeloid cells with a significant reduction of erythroid cells, associated with anemia. The IHC analysis of whole lyz:hMYC zebrafish showed infiltration of myeloid cells into different organs confirming that those cells can proliferate unconditionally and metastasise. May-Grunwald analysis showed a higher number of blast cells unable to differentiate towards mature granulocytes in lyz:hMYC zebrafish than in their wild type siblings. The gene expression profile of WKM demonstrated the overexpression of exogenous MYC and of endogenous myc, suggesting a positive auto-regulation of MYC. Metagenomic analysis revealed that the gut microbes of AML fish were significantly altered with the possibility to be associated the progression of AML.
Conclusions
The model developed here is an excellent tool to further understand the mechanisms involved in MYC-induced AML and the relevance of gut microbiota on this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Murcia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18